相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non-Small Cell Lung Cancer
Kimio Yonesaka et al.
CLINICAL CANCER RESEARCH (2022)
Prospective Identification of Elevated Circulating CDCP1 in Patients Years before Onset of Lung Cancer
Sonia Dagnino et al.
CANCER RESEARCH (2021)
CDCP1 enhances Wnt signaling in colorectal cancer promoting nuclear localization of β-catenin and E-cadherin
Yaowu He et al.
ONCOGENE (2020)
Mechanisms of resistance to osimertinib
Chiara Lazzari et al.
JOURNAL OF THORACIC DISEASE (2020)
Strategies to overcome acquired resistance to EGFR TKI in the treatment of non-small cell lung cancer
J. Gao et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2019)
DS-1205b, a novel selective inhibitor of AXL kinase, blocks resistance to EGFR-tyrosine kinase inhibitors in a non-small cell lung cancer xenograft model
Takeshi Jimbo et al.
Oncotarget (2019)
S100A10 Is a Critical Mediator of GAS6/AXL-Induced Angiogenesis in Renal Cell Carcinoma
Yiren Xiao et al.
CANCER RESEARCH (2019)
Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in EGFR-Mutant Non-Small Cell Lung Cancer Cells
Kei Namba et al.
MOLECULAR CANCER RESEARCH (2019)
AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells
Hirokazu Taniguchi et al.
NATURE COMMUNICATIONS (2019)
Osimertinib and pterostilbene in EGFR-mutation-positive non-small cell lung cancer (NSCLC)
Jillian Wilhelmina Paulina Bracht et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2019)
Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer
Suresh S. Ramalingam et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-smallcell Lung Cancer Associated With Poor Prognosis
Niki Karachaliou et al.
EBIOMEDICINE (2018)
Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion
Zofia Piotrowska et al.
CANCER DISCOVERY (2018)
Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T79OM-Positive Lung Cancer and Acquired Resistance to Osimertinib
Geoffrey R. Oxnard et al.
JAMA ONCOLOGY (2018)
Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC
Xiuning Le et al.
CLINICAL CANCER RESEARCH (2018)
Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC
Imane Chaib et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib
Chao-Chi Ho et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Characterization of In Vivo Resistance to Osimertinib and JNJ-61186372, an EGFR/Met Bispecific Antibody, Reveals Unique and Consensus Mechanisms of Resistance
Kristina B. Emdal et al.
MOLECULAR CANCER THERAPEUTICS (2017)
The activation of SRC family kinases and focal adhesion kinase with the loss of the amplified, mutated EGFR gene contributes to the resistance to afatinib, erlotinib and osimertinib in human lung cancer cells
Yuichi Murakami et al.
ONCOTARGET (2017)
Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC
Imane Chaib et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer
Eiki Ichihara et al.
CANCER RESEARCH (2017)
Molecular Pathways: AXL, a Membrane Receptor Mediator of Resistance to Therapy
Maurizio Scaltriti et al.
CLINICAL CANCER RESEARCH (2016)
Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study
Glenwood Goss et al.
LANCET ONCOLOGY (2016)
Overcoming drug resistance to receptor tyrosine kinase inhibitors: Learning from lung cancer
Michihiko Kuwano et al.
PHARMACOLOGY & THERAPEUTICS (2016)
CUB domain-containing protein 1 and the epidermal growth factor receptor cooperate to induce cell detachment
Mary E. Law et al.
BREAST CANCER RESEARCH (2016)
EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients
D. Planchard et al.
ANNALS OF ONCOLOGY (2015)
The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies
Matthew J. Niederst et al.
CLINICAL CANCER RESEARCH (2015)
Mechanisms of Acquired Resistance to AZD9291 A Mutation-Selective, Irreversible EGFR Inhibitor
Tae Min Kim et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M
Kenneth S. Thress et al.
NATURE MEDICINE (2015)
CUB-domain-containing protein 1 overexpression in solid cancers promotes cancer cell growth by activating Src family kinases
C. Leroy et al.
ONCOGENE (2015)
Interaction of CDCP1 with HER2 Enhances HER2-Driven Tumorigenesis and Promotes Trastuzumab Resistance in Breast Cancer
Abdullah Alajati et al.
CELL REPORTS (2015)
Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain
Helena A. Yu et al.
JAMA ONCOLOGY (2015)
Tyrosine Phosphoproteomics Identifies Both Codrivers and Cotargeting Strategies for T790M-Related EGFR-TKI Resistance in Non-Small Cell Lung Cancer
Takeshi Yoshida et al.
CLINICAL CANCER RESEARCH (2014)
Src mediates ERK reactivation in gefitinib resistance in non-small cell lung cancer
Nobuaki Ochi et al.
EXPERIMENTAL CELL RESEARCH (2014)
Oncogenic Ras/ERK Signaling Activates CDCP1 to Promote Tumor Invasion and Metastasis
Takamasa Uekita et al.
MOLECULAR CANCER RESEARCH (2014)
Genetic modifiers of EGFR dependence in non-small cell lung cancer
Tanaz Sharifnia et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET
Erinn B. Rankin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
The TAM family: phosphatidylserine-sensing receptor tyrosine kinases gone awry in cancer
Douglas K. Graham et al.
NATURE REVIEWS CANCER (2014)
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
Helena A. Yu et al.
CLINICAL CANCER RESEARCH (2013)
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
Lecia V. Sequist et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
HGF induces novel EGFR functions involved in resistance formation to tyrosine kinase inhibitors
S. Gusenbauer et al.
ONCOGENE (2013)
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Rafael Rosell et al.
LANCET ONCOLOGY (2012)
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
Zhenfeng Zhang et al.
NATURE GENETICS (2012)
Blocking of CDCP1 cleavage in vivo prevents Akt-dependent survival and inhibits metastatic colonization through PARP1-mediated apoptosis of cancer cells
B. Casar et al.
ONCOGENE (2012)
New Strategies in Overcoming Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer
Geoffrey R. Oxnard et al.
CLINICAL CANCER RESEARCH (2011)
Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma.
Tony S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
CUB domain-containing protein 1 is a novel regulator of Anoikis resistance in lung adenocarcinomavt
Takamasa Uekita et al.
MOLECULAR AND CELLULAR BIOLOGY (2007)
Adhesion or plasmin regulates tyrosine phosphorylation of a novel membrane glycoprotein p80/gp140/CUB domain-containing protein 1 in epithelia
TA Brown et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
分享论文
